FDA Approves Osmolex, by Osmotica, to Treat Movement Problems in Parkinson’s and Other Adults

FDA Approves Osmolex, by Osmotica, to Treat Movement Problems in Parkinson’s and Other Adults
The U.S. Food and Drug Administration (FDA) has approved Osmolex ER (amantadine, extended release) to treat both Parkinson’s disease and therapy-induced extrapyramidal reactions in adults, or the movement and muscle-control problems that typify this disease and can be side effects of common medications. Osmodex ER, developed and marketed by Osmotica Pharmaceutical, is a once-daily tablet that contains a combination of immediate release ... read more
Source: Parkinson’s News TodayPublished on 2018-02-22By Patricia Inacio, PhD